A Selective Cysteinyl Leukotriene Receptor 2 Antagonist Blocks Myocardial Ischemia/Reperfusion Injury and Vascular Permeability in Mice
Authors:
- Tim St. AmandTATim St. Amand
- Derek A. PrattDPDerek A. Pratt
- Colin D. FunkCFColin D. Funk
Open Access
- 1 December 2011
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 339 (3) , 768-778
Abstract
Cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators that predominantly exert their effects by binding to cysteinyl leukotriene receptors of the G protein-coupled receptor family. CysLT receptor 2 (CysLT2R), expressed in endothelial cells of some vascular beds, has been implicated in a variety of cardiovascular functions. Endothelium-specific overexpression of human CysLT2R in transgenic mice (hEC-CysLT2R) greatly increases myocardial infarction damage. Investigation of this receptor, however, has been hindered by the lack of selective pharmacological antagonists. Here, we describe the characterization of 3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)-propoxy)benzoic acid (BayCysLT2) and explore the selective effects of this compound in attenuating myocardial ischemia/reperfusion damage and vascular leakage. Using a recently developed β-galactosidase–β-arrestin complementation assay for CysLT2R activity (Mol Pharmacol 79:270–278, 2011), we determined BayCysLT2 to be ∼20-fold more potent than the nonselective dual CysLT receptor 1 (CysLT1R)/CysLT2R antagonist 4-(((1R,2E,4E,6Z,9Z)-1-((1S)-4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraen-1-yl)thio)benzoic acid (Bay-u9773) (IC50 274 nM versus 4.6 μM, respectively). Intracellular calcium mobilization in response to cysteinyl leukotriene administration showed that BayCysLT2 was >500-fold more selective for CysLT2R compared with CysLT1R. Intraperitoneal injection of BayCysLT2 in mice significantly attenuated leukotriene D4-induced Evans blue dye leakage in the murine ear vasculature. BayCysLT2 administration either before or after ischemia/reperfusion attenuated the aforementioned increased myocardial infarction damage in hEC-CysLT2R mice. Finally, decreased neutrophil infiltration and leukocyte adhesion molecule mRNA expression were observed in mice treated with antagonist compared with untreated controls. In conclusion, we present the characterization of a potent and selective antagonist for CysLT2R that is useful for discerning biological activities of this receptor.Keywords
This publication has 33 references indexed in Scilit:
- Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT 2 receptorThe FASEB Journal, 2011
- Characterization of the Cysteinyl Leukotriene 2 Receptor in Novel Expression Sites of the Gastrointestinal TractThe American Journal of Pathology, 2011
- Increased expression of leukotriene C4synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysmProceedings of the National Academy of Sciences, 2010
- The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl‐leukotrienes receptorThe EMBO Journal, 2006
- A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarctionNature Genetics, 2005
- Leukotriene modifiers as potential therapeutics for cardiovascular diseaseNature Reviews Drug Discovery, 2005
- Directed Vascular Expression of Human Cysteinyl Leukotriene 2 Receptor Modulates Endothelial Permeability and Systemic Blood PressureCirculation, 2004
- The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and strokeNature Genetics, 2004
- Characterization of the Human Cysteinyl Leukotriene 2 ReceptorJournal of Biological Chemistry, 2000
- Mild Selective Hydrolysis of the Methyl Esters of someortho-Substituted Aromatic Carboxylic AcidsSynthesis, 1981